Endothelialmineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity

European Heart Journal

Volumn 34, Issue 45, 2013, Pages 3515-3524

  Schäfer, Nicola ^a   Lohmann, Christine ^a   Winnik, Stephan ^a   Van Tits, Lambertus J ^a   Miranda, Melroy X ^a   Vergopoulos, Athanasios ^b   Ruschitzka, Frank ^a   Nussberger, Jürg ^c   Berger, Stefan ^d   Lü scher, Thomas F ^a   Verrey, François ^a   Matter, Christian M ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Aldosterone; Endothelial; Mineralocorticoid receptor; Obesity

Indexed keywords

ACETYLCHOLINE; CYCLOOXYGENASE 1; EPLERENONE; INDOMETACIN; MINERALOCORTICOID RECEPTOR; PROSTACYCLIN SYNTHASE; ALDOSTERONE; ANTIOXIDANT; COPPER ZINC SUPEROXIDE DISMUTASE; CYTOCHROME P450; DRUG DERIVATIVE; GLUTATHIONE PEROXIDASE; GLUTATHIONE PEROXIDASE 1; ISOMERASE; MINERALOCORTICOID ANTAGONIST; PROSTAGLANDIN SYNTHASE INHIBITOR; SPIRONOLACTONE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HYPERGLYCEMIA; INFLAMMATION; LIPID DIET; LOSS OF FUNCTION MUTATION; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; UPREGULATION; VASCULAR RING; WHITE ADIPOSE TISSUE; ADIPOSE TISSUE; ANIMAL; AORTA; C57BL MOUSE; DRUG EFFECT; ENDOTHELIAL; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ALDOSTERONE; ENDOTHELIAL; MINERALOCORTICOID RECEPTOR; OBESITY;

ADIPOSE TISSUE; ALDOSTERONE; ANIMALS; ANTIOXIDANTS; AORTA; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DIET, HIGH-FAT; ENDOTHELIUM, VASCULAR; GLUTATHIONE PEROXIDASE; HYPERGLYCEMIA; INFLAMMATION; INTRAMOLECULAR OXIDOREDUCTASES; MALE; MICE; MICE, INBRED C57BL; MINERALOCORTICOID RECEPTOR ANTAGONISTS; OBESITY; OXIDATIVE STRESS; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE; SUPEROXIDE DISMUTASE; UP-REGULATION;

EID: 84888054524     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht095     Document Type: Article

References (40)

1. James PT, Rigby N, Leach R. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehab 2004;355:763-778.
2. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell 2001; 104:531-543.
3. Ahima RS. Adipose tissue as an endocrin organ. Obesity 2006;14:242S-249S.
4. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115:1111-1119.
5. Erhardt-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci USA 2003;100:14211-14216.
6. Goodfriend TL, Egan BM, Kelley DE. Aldosterone in obesity. Endocr Res 1998;24: 789-796.
7. Pitt B, Remme W, Zannad F. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
8. Pitt B, Zannad F, Remme WJ. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717.
9. Garnier A, Bendall JK, Fuchs S, Escoubet B, Rochais F, Hoerter J, Nehme J, Ambroisine ML, Angelis ND, Morineau G, d'Estienne P, Fischmeister R, Heymes C, Pinet F, Declayre C. Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-Transgenic mice. Circulation 2004;110:1819-1825.
10. Tang EH, Ku D, Tipoe GL, Feletou M, Man RY, Vanhoutte PM. Endotheliumdependent contractions occur in the aorta of wild-Type and COX2-/-knockout but not COX1-/-knockout mice. J Cardiovasc Pharmacol 2005;46:761-765.
11. Luscher TF, Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension 1986;344: 344-348.
12. Leopold JA, Cap A, Scribner AW, Stanton RC, Loscalzo L. Glucose-6-phosphate dehydrogenase deficiency promotes endothelial oxidative stress and decreases endothelial nitric oxide bioviability. FASEB J 2001;15:1771-1773.
13. Hoen PAC, Lans CACVd, Eck MV, Bijsterbosch MK, Berkel TJCV, Twisk J. Aorta of ApoE-deficient mice responds to atherogenic stimuli by a prelesional increase and susequent decrease in the expression of antioxidant enzymes. Circ Res 2003; 93:262-269.
14. Sorescu D, Weiss D, Lassegue B, Clempus RE, Szö cs K, Sorescu GP, Valppu L, Quinn MT, Lambeth JD, Vega JD, Taylor R, Griendling KK. Superoxide production and expression of Nox family proteins in human atherosclerosis. Circulation 2002; 105:1429-1435.
15. Suzuki J, Iwai M, Mogi M, Oshita A, Yoshii T, Higaki J, Horiuchi M. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 2006;26:917-921.
16. Sartorio CL, Fraccarollo D, Galuppo P, Leutke M, Ertl G, Stefanon I, Bauersachs J. Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. Hypertension 2007;50: 919-925.
17. Iwashima F, Yoshimoto T, Minami I, Sakurada M, Hirono Y, Hirata Y. Aldosterone induces superoxide generation via rac1 activation in endothelial cells. Endocrinology 2008;149:1009-1014.
18. Blanco-Rivero J, Cachofeiro V, Lahera V, Aras-Lopez R, Márquez-Rodas I, Salaices M, Xavier FE, Ferrer M, Balfagón G. Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats. Hypertension 2005;46:107-112.
19. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo J. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 2007;13:189-197.
20. Caprio M, Newfell B, Sala Al, Baur W, Fabbri A, Rosano G, Mendelsohn ME, Jaffe IZ. Functional mineralocorticoid receptor in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 2008;102:1359-1367.
21. Caprio M, Feve B, Claes A, Viengchareun S, Lombes M. Pivotal role of the mineralocorticoid receptor in corticoid-induced adipogenesis. FASEB J 2007;21:1-10.
22. Guo C, Ricchiuti V, Lian BQ, Yao TM, Couthino P, Romero JR, Li J, Wiliams GH, Adler G. Mineralocorticoid receptor blockade reserves obesity-related changes in expression of adiponectin, peroxisome proliferator-Activated receptor-gamma, and pro-inflammatory adipocytokines. Circulation 2008;117:2253-2261.
23. Hirata A, Maeda N, Hiuge A, Hibuse T, Fujita K, Okada T, Kihara S, Funahashi T, Shimomura I. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 2009;84:164-172.
24. Yamaji M, Tsutamoto T, Kawahara C, Nishiyama K, Yamamoto T, Fujii M, Horie M. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure. Am Heart J 2012;160:915-921.
25. Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res 1999;7:355-361.
26. Rocchini AP, Key J, Bondie D, Chico R, Moorehead C, Katch V, Martin M. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med 1989;321:580-585.
27. Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 2004;43: 358-363.
28. Hlavacova N, Jezova D. Effects of single treatment with the antihypertensive drug eplerenone on hormone levels and anxiety-like behaviour in rats. Endocr Regul 2008;42:147-153.
29. Krum H, Nolly H,Workman D, HeW, Roniker B, Krause S, Fakouhi K. Efficacy of eplerenone added to renin-Angiotensin blockade in hypertensive patients. Hypertension 2002;40:117-123.
30. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K, Kasuga M. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006;116:1494-1505.
31. Avogaro A, de Kreutzenberg SV. Mechanisms of endothelial dysfunction in obesity. Clin Chim Acta 2005;360:9-26.
32. Xavier FE, Aras-Lopez R, Arroyo-Villa I, Campo LD, Salaices M, Rossoni LV, Ferrer M, Balfagon G. Aldosterone induces endothelial dysfunction in resistance arteries from normotensive and hypertensive rats by increasing thromboxane A2 and prostacyclin. Br J Pharmacol 2008;154:1225-1235.
33. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002;283:H1802-H1810.
34. Traupe T, Lang M, Goettsch W, Münter K, Morawietz H, Vetter W, Barton M. Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxan receptor gene expression. J Hypertens 2002;20:2239-2245.
35. Félétou M, Huang Y, Vanhoutte P. Vasoconstrictor prostanoids. Pflügers Archiv 2010;459:941-950.
36. Gros R, Ding Q, Sklar LA, Prossnitz EE, Arterburn JB, Chorazyczewski J, Feldman RD. GPR30 expression is required for the mineralocorticoid receptorindependent rapid vascular effects of aldosterone. Hypertension 2011;57:442-451.
37. Nguyen Dinh Cat A, Griol-Charhbili V, Loufrani L, Labat C, Benjamin L, Farman N, Lacolley P, Henrion D, Jaisser F. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J 2010;24: 2454-2463.
38. Gomez-Sanchez CE, de Rodriguez AF, Romero DG, Estess J, Warden MP, Gomez-Sanchez MT, Gomez-Sanchez EP. Development of a panel of monoclonal antibodies against the mineralocorticoid receptor. Endocrinology 2006;147: 1343-1348.
39. Alva JA, Zovein AC, Monvoisin A, Murphy T, Salazar A, Harvey NL, Carmeliet P, Iruela-Aispe ML. VE-Cadherin-Cre-recombinase transgenic mouse: A tool for lineage analysis and gene deletion in endothelial cells. Dev Dynam 2006;235: 759-767.
40. Bienvenu LA, Morgan J, Rickard AJ, Tesch GH, Cranston GA, Fletcher EK, Delbridge LM, Young MJ. Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis. Endocrinology 2012; 153:3416-3425.